Detection of minimal residual disease in multiple myeloma and acute leukaemia

Medical Oncology

Volumn 13, Issue 2, 1996, Pages 121-131

  Bakkus, Marleen H C ^a   Juge Morineau, Nadine ^a   Van Der Werff Ten Bosch, Jutte E ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Acute leukaemia; Minimal residual disease; Multiple myeloma; Polymerase chain reaction

Indexed keywords

ACUTE LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CYTOGENETICS; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0030478185     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02993863     Document Type: Review

References (88)

1. Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris, J. and Laurent, G. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood 79, 1130-6.
2. Jagannath, S., Vesole, D.H., Glenn, L., Crowley, J. and Barlogie, B. (1992) Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem-cell support. Blood 80, 1666-72.
3. Kyle, R.A. (1990) Newer approaches to the therapy of multiple myeloma. Blood 76, 1678-9.
4. Sonta, S.I. and Sandberg, A.A. (1977) Chromosomes and causation of human cancer and leukemia: XXVIII. Value of detailed chromosome studies on large numbers of cells in CML. Am. J. Hematol. 3, 121-6.
5. Hittelman, W.N., Tigaud, J.-D., Estey, E. and Vadhan-Raj, S. (1990) Premature chromosome condensation in the study of minimal residual disease. Bone Marrow Transpl. 6, 9-13.
6. Estrov, Z. and Freedman, M.H. (1988) Growth requirements for human acute lymphoblastic leukemia cells: Refinement of a clonogenic assay. Cancer Res. 48, 5901-7.
7. Gerhartz, H.H. and Schmetzer, H. (1990) Detection of minimal residual disease in acute myeloid leukemia. Leukemia 4, 508-16.
8. Van Dongen, J.J.M., Hooijkaas, H., Adriaansen, H.J., Hählen, K. and Van Zanen, G.E. (1986) Detection of minimal residual acute lymphoblastic leukemia by immunological marker analysis: Possibilities and limitations, In: A. Hagenbeek and B. Löwenberg (eds) Minimal residual disease in acute leukemia, pp. 113-33. Dordrecht: Nijhoff, M.
9. Delwel, R., Van Gurp, R., Bot, F., Touw, I. and Löwenberg, B. (1988) Phenotyping of acute myelocytic leukemia (AML) progenitors: An approach for tracing minimal numbers of AML cells among normal bone marrow. Leukemia 2, 814-9.
10. Campana, D., Coustan-Smith, E. and Janossy, G. (1990) The immunologic detection of minimal residual disease in acute leukemia. Blood 76, 163-71.
11. Wright, J.J., Poplack, D.G., Bahshi, A., Reaman, G., Cole, D., Jensen, J.P. and Korsmeyer, S.J. (1987) Gene rearrangements as markers of clonal variation and minimal residual disease in acute leukemias. J. Clin. Oncol. 5, 735-41.
12. Van Dongen, J.J.M. and Wolvers-Tettero, I.L.M. (1991) Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. Clin. Chim. Acta 198, 1-91.
13. Van Dongen, J.J.M., Hooijkaas, H., Hählen, K., Benne, K., Bitter, W.M., Van der Linde-Preesman, A.A., Tettero, I.L.M., Van de Rijn, M., Hilgers, J., Van Zanen, G.E. and Hagemeijer, A. (1984) Detection of minimal residual disease in TdT positive T cell malignancies by double immunofluorescence staining, In: B. Löwenberg and A. Hagenbeek (eds) Minimal residual disease in acute leukemia, pp. 67-81. The Hague: Nijhoff, M.
14. Bartram, C.R., Yokota, S., Hansen-Hagge, T.E. and Janssen, J.W.G. (1990) Detection of minimal residual leukemia by polymerase chain reactions. Bone Marrow Transpl. 6s, 4-8.
15. Campana, D., Yokota, S., Coustan-Smith, E., Hansen-Hagge, T.E., Janossy, G. and Bartram, C.R. (1990) The detection of acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: A comparative study. Leukemia 4, 609-14.
16. Lee, M.S., Chang, K.S., Cabanillas, F., Freireich, E.J., Trujillo, J.M. and Stass, S.A. (1987) Detection of minimal residual cells carrying the t(8;14) by DNA sequence amplification. Science 237, 175-8.
17. Van Bekkum, D.W. (1984) Residual reflection on the detection and treatment of leukemia, In: B. Löwenberg and A. Hagenbeek (eds) Minimal disease in acute leukemia, pp. 385-96. Boston: Nijhoff, M.
18. Mellstedt, H., Holm, G. and Bjorkholm, M. (1984) Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy. Adv. Cancer Res. 41, 257-89.
19. Van Dyk, L. and Meek, K. (1992) Assembly of IgH CDR3: Mechanism, regulation and influence on antibody. Int. Rev. Immunol. 8, 123-33.
20. Ralph, Q.M., Brisco, M.J., Joshua, D.E., Brown, R., Gibson, J. and Morley, A.A. (1993) Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone - evidence from the Ig heavy chain gene. Blood 82, 202-6.
21. Bakkus, M.H.C., Heirman, C., Van Riet, I., Van Camp, B. and Thielemans, K. (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80, 2326-35.
22. Bird, J.M., Russell, N.H. and Samson, D. (1993) Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant. 12, 651-4.
23. Bird, J.M., Bloxham, D., Samson, D., Marcus, R.E., Russell, N.H., Kelsey, S.M., Newland, A.C. and Apperley, J.F. (1994) Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br. J. Haematol. 88, 110-6.
24. Deane, M., McCarthy, K.P., Wiedemann, L.M. and Norton, J.D. (1991) An improved method for detection of B-lymphoid clonality by the polymerase chain reaction. Leukemia 5, 726-30.
25. Dreyfus, F., Melle, J., Quarre, M.-C. and Pillier, C. (1993) Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high-dose chemotherapy. Br. J. Haematol. 85, 411-2.
26. Björkstrand, B., Ljungman, P., Bird, J.M., Samson, D. and Gahrton, G. (1995) Double high-dose chemotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant. 15, 367-71.
27. Bakkus, M.H.C., Van Riet, I., Jochmans, K., Lacor, P., Van Camp, B. and Thielemans, K. (1991) Detection of residual multiple myeloma cells by PCR in blood stem cell concentrates after GM-CSF treatment. In: J. Radl and B. Van Camp (eds) Monoclonal gammapathies III-Clinical significance and basic mechanisms, pp. 183-6. Leiden: Eurage.
28. Billadeau, D., Blackstadt, M., Greipp, P., Kyle, R.A., Oken, M.M., Kay, N. and Van Ness, B. (1991) Analysis of B-lymphoid malignancies using allele-speciftc polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 78, 3021-9.
29. Billadeau, D., Quam, L., Thomas, W., Kay, N., Greipp, P., Kyle, R., Oken, M.M. and Van Ness, B. (1992) Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma. Blood 80, 1818-24.
30. Takishita, M., Kosaka, M., Goto, T. and Saito, S. (1994) Cellular origin and extend of clonal involvement in multiple myeloma: genetic and phenotypic studies. Brit. J. Haematol. 87, 735-42.
31. Corradini, P., Voena, C., Omedé, P., Astolfi, M., Boccadoro, M., Dalla-Favera, R. and Pileri, A. (1993) Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 7, 1879-82.
32. Corradini, P., Voena, C., Astolfi, M., Ladetto, M., Tarella, C., Boccadoro, M. and Pileri, A. (1995) High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85, 1596-602.
33. Bakkus, M.H.C., Van Riet, I., Van Camp, B. and Thielemans, K. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Brit. J. Haematol. 87, 68-74.
34. Corradini, P., Astolfi, M., Ladetto, M., Campana, S., Comoglio, F., Tarella, C., Boccadoro, M. and Pileri, A. (1995) High-dose (HDS) chemotherapy in multiple myeloma: residual tumor cells are detectable in PBPC and BM cell harvests and after single or double autografting. Blood 86(suppl), 206a.
35. Yeh, K.-H., Lin, M.-T., Tang, J.-L., Yang, C.-H., Tsay, W. and Chen, Y.-C. (1995) Long-term disease-free survival after autologous bone marrow transplantation in primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. Br. J. Haematol. 89, 914-6.
36. Samson, D., Lyttelton, M.P., Elliot, C.J., Bybee, A., Gupta, D., Armitage, S., Mcguigan, D., Wilmore, H.P. and Kanfer, E.J. (1995) CD34+ selected peripheral blood progenitor cell transplantation after high-dose melphalan and TBI in multiple myeloma: feasibility, toxicity and tumor cell contamination. Blood 86(suppl), 963a.
37. Dreyfus, F., Ribrag, V., Leblond, V., Ravaud, P., Melle, J., Quarre, M.C., Pillier, C., Boccaccio, C. and Varet, B. (1995) Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 15, 707-11.
38. Mariette, X., Fermand, J.P. and Brouet, J.C. (1994) Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant. 14, 47-50.
39. Henry, J.M., Sykes, P.J., Brisco, M.J., Bik TO, L., Juttner, A. and Morley, A.A. (1996) Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br. J. Haematol. 92, 614-9.
40. Vescio, R.A., Hong, C.H., Cao, J., Kim, A., Schiller, G.J., Lichtenstein, A.K., Berenson, R.J. and Berenson, J.R. (1994) The hematopoietic stem cell antigen, CD34 is not expressed on the malignant cells in multiple myeloma. Blood 84, 3283-90.
41. Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., Wu, C-H., Cao, J., Lee, J.C., Hong, C.H., Lichtenstein, A., Lill, M., Hall, J., Berenson, R. and Berenson, J. (1995) Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86, 390-7.
42. Willems, P., Croockewit, R., Raymakers, R., Holdrinet, G., van der Bosch, G., Huys, E. and Mensink, E. (1996) CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not CD34+ myeloma cells. Br. J. Haematol. 93, (in press).
43. Van Riet, I., Schots, R., Juge, N., De Waele, M., Servotte, S., Lacor, P., Van Camp, B. and Bakkus, M. (1995) Cytokine-mediated generation of myeloid progenitors in stroma-free cultures of mobilized CD34+ blood cells: no evidence for tumor cell expansion in multiple myeloma. Blood 86(suppl), 62a.
44. Gazitt, Y., Reading, C.C., Hoffman, R., Wickrema, A., Vesole, D.H., Jagannath, S., Condino, J., Lee, B., Barlogie, B. and Tricot, G. (1995) Purified CD34(+) Lin(-) Thy(+) stem cells do not contain clonal myeloma cells. Blood 86, 381-9.
45. Gertz, M.A., Witzig, T.E., Pineda, A.A., Greipp, P.R., Kyle, R.A. and Litzow, M.R. (1995) Monotypic plasma cells in the peripheral blood stem cell harvest of patients with multiple myeloma is associated with shortened relapse-free survival following transplantation. Blood 86(suppl. 1), 207a.
46. Vervoordeldonk, S.F., Merle, P.A., Behrendt, H., Steenbergen, E.J., van Leeuwen, E.F., van den Berg, H., von dem Borne, A.E.G.K., van der Schoot, C.E. and Slaper-Cortenbach, I.C.M. (1996) Triple immunofluorescence staining for prediction of relapse in childhood precursor acute lymphoblastic leukaemia. Br. J. Haematol. 92, 922-8.
47. van Dongen, J.J., Breit, T.M., Adriaansen, H.J., Beishuizen, A. and Hooijkaas, H. (1992) Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 6(suppl.1), 47-59.
48. Copelan, E.A. and McGuire, E.A. (1995) The biology and treatment of acute lymphoblastic leukemia in adults. Blood 85, 1151-68.
49. Freireich, E.J., Cork, A., Stass, S.A., McCredie, K.B., Keating, M.J., Estey, E.H., Kantarjian, H.M. and Trujillo, J.M. (1992) Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6, 500-6.
50. Nylund, S.J., Ruutu, T., Saarinen, U., Larramendy, M.L. and Knuutila, S. (1994) Detection of minimal residual disease using fluorescence DNA in situ hybridisation. A follow-up study in leukemia and lymphoma patients. Leukemia 8, 587-94.
51. Campana, C. and Ching-Hon Pui, C.-H. (1995) Detection of minimal residual disease in acute leukemia. Methodologic advances and clinical significance. Blood 85, 1151-68.
52. Longo, L., Pandolfi, P.P., Biondi, A., Rambaldi, A., Mencarelli, A., Lo Coco, F., Diveria, D., Pegoraro, L., Avanzi, G., Tabilio, A., Zangrilli, D., Alcalay, M., Donti, E., Grignani, F. and Pelicci, P.G. (1990) Rearrangements and aberrant expression of the retinoic acid receptor α gene in acute promyelocytic leukemias. J. Exp. Med. 172, 1571-5.
53. Huang, W., Sun, G.-L., Li, X.-S., Cao, Q., Lu, Y., Jang, G.-S., Zhang, F.Q., Chai, J.-R., Wang, Z.-Y., Waxman, S., Chen, Z. and Chen, S.-J. (1993) Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 82, 1264-9.
54. Lo Coco, F., Diverio, D., Pandolfi, P.P., Biondi, A., Rossi, V., Avvisati, G., Rambaldi, A., Arcese, W., Petti, M.C., Meloni, G., Mandelli, F., Grignani, F., Masera, G., Barbui, T. and Pelicci, P.G. (1992) Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. The Lancet 340, 1437-8.
55. Miller Jr, W.H., Levine, K., DeBlasio, A., Frankel, S.R., Dmitrovsky, E. and Warrell Jr, R.P. (1993) Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RARa fusion mRNA. Blood 82, 1689-94.
56. Kusec, R., Laczika, K., Knöbl, P., Friedl, J., Greinix, H., Kahls, P., Linkesh, W., Schwartzinger, I., Mitterbauer, G., Purtscher, B., Haas, O.A., Lechner, K. and Jaeger, U. (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8, 735-9.
57. Downing, J.R., Head, D.R., Curcio-Brint, A.M., Hulshof, M.G., Montroni, T.A., Raimondi, S.C., Carroll, A.J., Drabkin, H.A., Willman, C., Theil, K.S., Civin, C.I. and Erickson, P. (1993) An AML1/ETO fusion transcript is consistently detected by RNA based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 81, 2860-5.
58. Maruyama, F., Stass, S.A., Estey, E.E., Cork, A., Hirano, M., Ino, T., Freirich, E.J., Yang, P. and Chang, K.-S. (1994) Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 8, 40-5.
59. Nucifora, G., Larson, R.A. and Rowley, J.D. (1993) Persistence of 8;21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 82, 712-5.
60. Claxton, D.F., Liu, P., Hsu, H.B., Marlton, P., Hester, J., Collins, F., Deisseroth, A.B., Rowley, J.D. and Siciliano, M.J. (1994) Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83, 1750-6.
61. Yamamoto, K., Iida, M.S., Komatsu, H., Kamada, N., Kojima, S., Kodera, Y., Nakazawa, S., Saito, H., Takahashi, T. and Ueda, R. (1994) A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemia with 11q23 abnormalities. Blood 83, 2912-21.
62. Cimino, G., Elia, L., Rivolta, A., Rapanotti, M.C., Rossi, V., Alimena, G., Annino, L., Canaani, E., Lo Coco, F. and Biondi, A. (1996) Clinical relevance of residual disease monitoring by polymerase chain reaction with ALL-1/AF-4 positive acute lymphoblastic leukemia. Br. J. Haematol. 92, 659-64.
63. Privitera, E., Rivolta, A., Ronchetti, D., Mosna, G., Giudici, G. and Biondi, A. (1996) Reverse transcriptase/ polymerase chain reaction follow-up and minimal residual disease detection in t(1;19) positive acute lymphoblastic leukemia. Br. J. Haematol. 92, 6653-8.
64. Hunger, S.P. (1996) Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87, 1211-24.
65. Devaraj, P.E., Foroni, L., Sekhar, M., Butler, T., Wright, F., Mehta, A., Samson, A., Prentice, H.G., Hoffbrand, A.V. and Secker-Walker, L.M. (1994) E2A/HLF fusion cDNAs and the use of RT-PCR for the detection of minimal residual disease in t(17;19)(q22;p13) acute lymphoblastic leukemia. Leukemia 8, 1131-8.
66. KIP1. Blood 86, 3869-75.
67. Raynaud, S., Cavé, H., Baens, M., Bastard, C., Cacheux, V., Grosgeorge, J., Guidal-Giroux, C., Guo, C., Vilmer, E., Marynen, P. and Grandchamp, B. (1996) The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 87, 2891-9.
68. Breit, T.M., Beishuizen, A., Ludwig, W.D., Mol, E.J., Adriaansen, H.J., van Wering, E.R. and van Dongen, J.J. (1993) Tal1 deletion in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 7, 2004-11.
69. Menssen, H.D., Renkl, H.J., Rodeck, U., Maurer, J., Notter, M., Schwartz, S., Reinhardt, R. and Thiel, E. (1995) Presence of Wilms' tumor gene (wt1) transcripts and the wt1 nuclear protein in the majority of human acute leukemias. Leukemia 9, 1060-7.
70. Beishuizen, A., Verhoeven, M.A., Hahlen, K., van Wering, E.R. and van Dongen, J.J. (1991) Differences in immunoglobulin heavy chain gene rearrangement patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leukemia at diagnosis. Leukemia 5, 657-67.
71. Breit, T.M., Wolvers-Tettero, I.L.M., Beishuizen, A., Verhoeven, M.J., van Wering, E.R. and van Dongen, J.J.M. (1993) Southern blot patterns, frequencies and junctional diversity of T-cell receptor δ gene rearrangements in acute lymphoblastic leukemia. Blood 82, 3063-74.
72. Van Dongen, J.J.M. and Wolvers-Tettero, I.L.M. (1991) Analysis of immunoglobulin and T-cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 198, 93-174.
73. Jonsson, O.G., Kitchens, R.L., Scott, F.C. and Smith, R.G. (1990) Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood 76, 2072-9.
74. Potter, M.N. (1992) The detection of minimal residual disease in acute lymphoblastic leukaemia. Blood Rev. 6, 68-82.
75. Beishuizen, A., Verhoeven, M.J., van Wering, E.R., Hahlen, K., Hooijkaas, H. and van Dongen, J.J.M. (1994) Analysis of the immunoglobulin and T-cell receptor genes in 40 childhood acute lymphoblastic leukemia at diagnosis and relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 83, 2238-47.
76. Steenbergen, E.J., Verhagen, O.J., van Leeuwen, E.F., van den Berg, H., von dem Borne, A.E. and van der Schoot, C.E. (1995) Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease. Blood 86, 692-702.
77. Cavé, H., Guidal, C., Rohrlich, P., Delfau, M.H., Broyart, A., Lescoeur, B., Rahimy, C., Fenneteau, O., Monplaisir, N., d'Auriol, L., Elion, J., Vilmer, E. and Grandchamp, B. (1994) Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 83, 1892-1902.
78. Norris, M.D., Kwan, E., Haber, M. and Marshall, G.M. (1995) Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJh primers. Leukemia 9, 1779-82.
79. Cavé, H., Bakkus, M., Suciu, S., Guidal, C., Fournier, M., Robert, A., Boutard, P., Mechinaud, F., Plouvier, E., Ferster, A., Nelken, B., Otten, J., Thielemans, K., Grandchamp, B. and Vilmer, E. (1995) Significance of the quantitation of minimal residual disease by PCR amplification of IGH and TCR gene rearrangements in childhood ALL: an EORTC prospective multicenter study. Blood 86(suppl), 178a.
80. Steenbergen, E.J., Verhagen, O.J.H.M., van Leeuwen, E.F., van den Berg, H., Behrendt, H., Slater, R.M., von dem Borne, A.E.G.K. and van der Schoot, C.E. (1995) Prolonged persistence of PCR detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 9, 1726-34.
81. Nizet, Y., Van Daele, S., Lewalle, P., Vaerman, J.L., Phillipe, M., Vermylen, C., Cornu, G., Ferrant, A., Michaux, J.L. and Martiat, P. (1993) Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 82, 1618-25.
82. Scholten, C., Fodinger, M., Mitterbauer, M., Laczika, K., Mittelbauer, G., Haas, O.A., Knobl, P., Schwarzinger, I., Thalhammer, R., Purtscher, B. et al. (1995) Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult lineage acute lymphoblastic leukemia. Ann. Hematol. 71, 155-60.
83. Biondi, A., Yokota, S., Hansen-Hagge, T.E., Rossi, V., Giudici, G., Maglia, O., Basso, G., Tell, C., Masera, G. and Bartram, C.R. (1992) Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 6, 282-8.
84. Neale, G.A.M., Menarguez, J., Kitchingman, G.R., Fitzgerald, T.J., Koehler, M., Mirro, J.J. and Goorha, R.M. (1991) Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 78, 739-47.
85. Yokota, S., Hansen-Hagge, T.E., Ludwig, W.D., Reiter, A., Raghavachar, A., Kleihauer, E. et al. (1991) Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77, 331-9.
86. Chim, J.C.S., Coyle, L.A., Yaxley, J.C., Cole-Sinclair, M.F., Cannell, P.K., Hoffbrand, V.A. and Foroni, L. (1996) The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease(MRD) in ALL. Br. J. Haematol. 92, 104-15.
87. Neale, G.A., Pui, C.H., Mahmoud, H.H., Mirro, J.J., Crist, W.M., Rivera, G.K. and Goorha, R.M. (1994) Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 8, 768-75.
88. Wasserman, R., Galili, N., Ito, Y., Silber, J.H., Reichard, B., Shane, S., Womer, R.B., Lange, B. and Rovera, G. (1992) Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 10, 1879-88.